Interestingly, the number of mutations per patient was not associated with time to AML (p > 0.05; Figure S2a), indicating that mutations in either STAG2, SRSF2 and/or RUNX1 are enough to predict early disease progression in isolated +8 MDS patients. This evidence concerns the gene RUNX1 and acute myeloid leukemia.